💨 Abstract

Isomorphic Labs, a spin-off from Google Deepmind, has secured $600 million in its first external funding round for AI-powered drug discovery. The funds will be used for accelerating research, development, and talent acquisition, with the goal of having AI-designed drugs in clinical trials by 2025. The investment highlights the growing interest in AI and machine learning startups amidst the surge in demand for generative AI.

Courtesy: theprint.in

Summarized by Einstein Beta 🤖